Northstar Wealth Partners LLC lowered its stake in shares of Johnson & Johnson (NYSE:JNJ) by 6.3% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 22,768 shares of the company’s stock after selling 1,521 shares during the period. Johnson & Johnson accounts for about 3.0% of Northstar Wealth Partners LLC’s investment portfolio, making the stock its 3rd largest position. Northstar Wealth Partners LLC’s holdings in Johnson & Johnson were worth $3,038,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other institutional investors also recently added to or reduced their stakes in the company. Intact Investment Management Inc. boosted its stake in shares of Johnson & Johnson by 0.9% during the third quarter. Intact Investment Management Inc. now owns 67,400 shares of the company’s stock valued at $8,761,000 after purchasing an additional 600 shares during the period. Traynor Capital Management Inc. boosted its stake in shares of Johnson & Johnson by 3.5% during the third quarter. Traynor Capital Management Inc. now owns 10,822 shares of the company’s stock valued at $1,401,000 after purchasing an additional 368 shares during the period. Crossmark Global Holdings Inc. purchased a new stake in shares of Johnson & Johnson during the third quarter valued at $10,634,000. SPC Financial Inc. boosted its stake in shares of Johnson & Johnson by 208.8% during the third quarter. SPC Financial Inc. now owns 11,611 shares of the company’s stock valued at $1,510,000 after purchasing an additional 7,851 shares during the period. Finally, Callahan Advisors LLC boosted its stake in shares of Johnson & Johnson by 1.0% during the third quarter. Callahan Advisors LLC now owns 102,145 shares of the company’s stock valued at $13,280,000 after purchasing an additional 979 shares during the period. Hedge funds and other institutional investors own 65.79% of the company’s stock.
A number of analysts have recently issued reports on JNJ shares. BTIG Research reissued a “sell” rating and set a $110.00 target price on shares of Johnson & Johnson in a research note on Wednesday, January 24th. Vetr downgraded Johnson & Johnson from a “buy” rating to a “hold” rating and set a $147.40 price objective for the company. in a report on Monday, January 8th. BMO Capital Markets lifted their price objective on Johnson & Johnson to $161.00 and gave the company an “outperform” rating in a report on Tuesday, December 12th. Credit Suisse Group set a $154.00 price objective on Johnson & Johnson and gave the company an “outperform” rating in a report on Thursday, October 19th. Finally, Zacks Investment Research downgraded Johnson & Johnson from a “buy” rating to a “hold” rating in a report on Tuesday, December 12th. Four research analysts have rated the stock with a sell rating, eight have issued a hold rating and ten have issued a buy rating to the stock. Johnson & Johnson presently has an average rating of “Hold” and a consensus target price of $146.16.
Johnson & Johnson (NYSE:JNJ) traded down $2.34 on Friday, hitting $137.68. 9,197,500 shares of the stock traded hands, compared to its average volume of 7,360,000. Johnson & Johnson has a 12-month low of $112.62 and a 12-month high of $148.32. The company has a current ratio of 1.32, a quick ratio of 1.02 and a debt-to-equity ratio of 0.36. The firm has a market capitalization of $369,880.00, a P/E ratio of 353.03, a P/E/G ratio of 2.47 and a beta of 0.74.
Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Tuesday, January 23rd. The company reported $1.74 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.72 by $0.02. The firm had revenue of $20.20 billion for the quarter, compared to the consensus estimate of $20.08 billion. Johnson & Johnson had a net margin of 1.70% and a return on equity of 27.80%. The company’s revenue for the quarter was up 11.5% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.58 earnings per share. research analysts expect that Johnson & Johnson will post 8.11 EPS for the current fiscal year.
The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 13th. Investors of record on Tuesday, February 27th will be given a $0.84 dividend. The ex-dividend date is Monday, February 26th. This represents a $3.36 dividend on an annualized basis and a yield of 2.44%. Johnson & Johnson’s dividend payout ratio is currently 861.54%.
COPYRIGHT VIOLATION WARNING: This piece of content was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this piece of content on another website, it was copied illegally and reposted in violation of U.S. and international trademark & copyright law. The correct version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/02/04/northstar-wealth-partners-llc-decreases-position-in-johnson-johnson-jnj.html.
About Johnson & Johnson
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.